Announcements
Sidley Represents Nektar Therapeutics in Its Sale of Its Manufacturing Facility and Reagent Supply Business
November 4, 2024
Sidley is representing Nektar Therapeutics in its US$90 million sale of its manufacturing facility and reagent supply business to Ampersand Capital Partners. The sale will help to streamline Nektar Therapeutics’ future operations as it looks to expand its development of core research and development programs in immunology.
The Sidley team is being led by Daniel J. Belke and Tommy Tsao (M&A and Private Equity) and Joshua T. Hofheimer and Lauren G. Grau (Technology and Life Sciences Transactions), and includes Antoinette R. Petkov and Lauren E. Dunn (M&A and Private Equity) and Sabrina K. Glavota (Technology and Life Sciences Transactions).
Contacts
Capabilities
Suggested News & Insights
Corporate College 2026Wednesday, October 14, 2026 - Thursday, October 15, 2026Sidley Represents Enbridge in US$2.55 Billion Acquisition of Tallgrass’ Crude Transportation BusinessSeptember 10, 2026Chambers 2026 Global Practice Guides – Private EquitySeptember 10, 2026Sidley Represents Vegamour in Its Acquisition by Belle BrandsSeptember 9, 2026Planning for the Impact of FinCEN’s Corporate Transparency Act RollbackSeptember 9, 2026Court of Chancery Confirms No Price-Maximization Duty on Public Benefit Corporation DirectorsSeptember 8, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory